|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0200 CAD | -33.33% |
|
-33.33% | -20.00% |
| 04-30 | NanoSphere Health Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| 04-29 | NanoSphere Health Sciences Inc. Auditor Raises 'Going Concern' Doubt | CI |
| Market Cap | 146K 128K 119K 110K 206K 14.12M 209K 1.42M 556K 6.89M 547K 536K 23.9M | P/E 2024 |
1.22x | P/E 2025 | -2.21x |
|---|---|---|---|---|---|
| Enterprise Value | 207K 182K 169K 156K 292K 20.08M 297K 2.03M 790K 9.79M 778K 762K 33.98M | EV / Sales 2024 |
-
| EV / Sales 2025 | - |
| Free-Float |
67.71% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | -33.33% | ||
| 1 week | -33.33% | ||
| 3 months | -20.00% | ||
| Current year | -20.00% |
| 1 week | 0.02 |  | 0.02 |
| 1 month | 0.02 | | 0.03 |
| Current year | 0.02 | | 0.03 |
| 1 year | 0.02 | | 0.06 |
| 3 years | 0 | | 0.18 |
| 5 years | 0 | | 0.38 |
| 10 years | 0 | | 23.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
Richard Kaufman
CTO | Chief Tech/Sci/R&D Officer | - | 2012-12-31 |
Bennett Liu
DFI | Director of Finance/CFO | 33 | 2017-10-31 |
Toby Lim
CEO | Chief Executive Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Michael Iverson
CHM | Chairman | 74 | 2019-07-09 |
Toby Lim
BRD | Director/Board Member | - | 2017-11-16 |
Richard Kaufman
BRD | Director/Board Member | - | 2017-11-16 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 9/17/21 | Sell | Chairman | 338,956 | 6.2564% | ||
| 9/17/21 | Sell | Chairman | 677,913 | 12.5128% | ||
| 9/17/21 | Other | Director | 0 | 0% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -33.33% | -33.33% | -33.33% | -33.33% | 219K | |
| +0.57% | +0.20% | +16.14% | +78.10% | 48.31B | |
| +2.34% | +1.55% | +61.25% | +111.71% | 35.33B | |
| -1.56% | -2.55% | -5.46% | +32.80% | 11.85B | |
| -1.11% | -3.48% | +15.79% | +81.64% | 11.64B | |
| -0.37% | -0.19% | +36.83% | +136.73% | 8.99B | |
| +1.54% | +0.54% | +49.01% | -5.69% | 6.93B | |
| -0.77% | -3.48% | +13.66% | +32.01% | 6.72B | |
| +0.24% | -3.58% | +3.10% | +192.78% | 6.43B | |
| +1.60% | -15.49% | -29.66% | +8.47% | 5.66B | |
| Average | -3.07% | -1.56% | +12.73% | +63.52% | 14.19B | |
| Weighted average by Cap. | +0.65% | -0.93% | +25.92% | +82.84% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | - |
| Net income | 263K 232K 215K 198K 371K 25.5M 378K 2.57M 1M 12.44M 989K 967K 43.15M | -84.78K -74.57K -69.27K -63.71K -119K -8.21M -122K -828K -323K -4M -318K -311K -13.89M |
| Net Debt | 28.69K 25.23K 23.44K 21.56K 40.43K 2.78M 41.15K 280K 109K 1.36M 108K 105K 4.7M | 61.51K 54.1K 50.26K 46.22K 86.69K 5.96M 88.24K 601K 234K 2.91M 231K 226K 10.08M |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-23 | $0.0200 | -33.33% | 2,000 |
- Stock Market
- Stocks
- NSHS Stock
Select your edition
All financial news and data tailored to specific country editions
